144 related articles for article (PubMed ID: 36319039)
21. Off-label use of oxaliplatin in patients with metastatic breast cancer.
Delpeuch A; Leveque D; Rob L; Bergerat JP
Anticancer Res; 2011 May; 31(5):1765-7. PubMed ID: 21617237
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy and toxicity of gemcitabine combined vinorelbine on metastatic breast cancer: a report of 34 cases].
Zhou NN; Teng XY; Jiang WQ; Liu DG
Ai Zheng; 2007 Dec; 26(12):1373-6. PubMed ID: 18076805
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine-oxaliplatin combination in heavily pretreated metastatic breast cancer: a pilot study on 43 patients.
Caruba T; Cottu PH; Madelaine-Chambrin I; Espié M; Misset JL; Gross-Goupil M
Breast J; 2007; 13(2):165-71. PubMed ID: 17319858
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine-Induced Retinopathy.
Jhaj G; Jhaj R; Shrier EM
Retina; 2017 Nov; 37(11):e130-e131. PubMed ID: 28961673
[No Abstract] [Full Text] [Related]
25. Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients.
Koshy N; Quispe D; Shi R; Mansour R; Burton GV
Breast; 2010 Jun; 19(3):246-8. PubMed ID: 20227277
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer.
Possinger K; Kaufmann M; Coleman R; Stuart NS; Helsing M; Ohnmacht U; Arning M
Anticancer Drugs; 1999 Feb; 10(2):155-62. PubMed ID: 10211545
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
McCarthy N; Boyle F; Zdenkowski N; Bull J; Leong E; Simpson A; Kannourakis G; Francis PA; Chirgwin J; Abdi E; Gebski V; Veillard AS; Zannino D; Wilcken N; Reaby L; Lindsay DF; Badger HD; Forbes JF;
Breast; 2014 Apr; 23(2):142-51. PubMed ID: 24393617
[TBL] [Abstract][Full Text] [Related]
28. High snail expression predicts a poor prognosis in breast invasive ductal carcinoma patients with HER2/EGFR-positive subtypes.
Chang HY; Tseng YK; Chen YC; Shu CW; Lin MI; Liou HH; Fu TY; Lin YC; Ger LP; Yeh MH; Liu PF
Surg Oncol; 2018 Jun; 27(2):314-320. PubMed ID: 29937187
[TBL] [Abstract][Full Text] [Related]
29. Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.
Halim A; Wahba H
Med Oncol; 2012 Jun; 29(2):454-8. PubMed ID: 21350875
[TBL] [Abstract][Full Text] [Related]
30. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
[TBL] [Abstract][Full Text] [Related]
31. [A case of bilateral multiple primary breast cancer].
Waga E; Sakurai K; Fujisaki S; Maeda T; Nagashima S; Hara Y; Tomita R; Suzuki S; Enomoto K; Amano S
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2036-8. PubMed ID: 23267968
[TBL] [Abstract][Full Text] [Related]
32. Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast.
Aguiar FN; Mendes HN; Bacchi CE; Carvalho FM
Rev Bras Ginecol Obstet; 2013 Mar; 35(3):97-102. PubMed ID: 23538467
[TBL] [Abstract][Full Text] [Related]
33. Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer.
Pusina S
Med Arch; 2018 Nov; 72(5):335-340. PubMed ID: 30524164
[TBL] [Abstract][Full Text] [Related]
34. Current and Emerging Therapies for HER2-Positive Women With Metastatic Breast Cancer.
Porter K; Rosenzweig MQ
J Adv Pract Oncol; 2017 Mar; 8(2):164-168. PubMed ID: 29900024
[No Abstract] [Full Text] [Related]
35. Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial.
Joensuu H; Sailas L; Alanko T; Sunela K; Huuhtanen R; Utriainen M; Kokko R; Bono P; Wigren T; Pyrhönen S; Turpeenniemi-Hujanen T; Asola R; Leinonen M; Hahka-Kemppinen M; Kellokumpu-Lehtinen P
Ann Oncol; 2010 May; 21(5):968-73. PubMed ID: 19819914
[TBL] [Abstract][Full Text] [Related]
36. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
[TBL] [Abstract][Full Text] [Related]
37. Gemcitabine and trastuzumab in metastatic breast cancer.
O'shaughnessy J
Semin Oncol; 2003 Apr; 30(2 Suppl 3):22-6. PubMed ID: 12722022
[TBL] [Abstract][Full Text] [Related]
38. The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breast.
Choi Y; Kim EJ; Seol H; Lee HE; Jang MJ; Kim SM; Kim JH; Kim SW; Choe G; Park SY
Hum Pathol; 2012 Jan; 43(1):48-55. PubMed ID: 21733550
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
[TBL] [Abstract][Full Text] [Related]
40. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]